Seer Highlights Proteomics at the American Society of Human Genetics
Seer, Inc. (Nasdaq: SEER), recognized as a leader in proteomic technology, is making waves in the realm of precision medicine at the recent American Society of Human Genetics (ASHG) Annual Meeting. This event, a pivotal gathering for professionals in human genetics, focuses on transitioning research from sequence-based methods to functional analyses. Seer’s involvement underscores the critical role proteomics plays in conjunction with genomics, significantly enriching our understanding of disease mechanisms.
Understanding the Role of Proteomics in Precision Medicine
At the ASHG annual event, taking place in Boston, Seer positions itself as a prominent contributor to cutting-edge discussions about the future of healthcare. The company is unveiling its Proteograph Product Suite, which aids researchers in transforming complex genomic data into actionable biological insights. This pivotal toolkit is not only aimed at enhancing the understanding of disease biology but is also essential for translating genomic entries into clinical applications.
Seer CoLab Session: Advancing Multi-Omics
One of the spotlight sessions is titled "Advancing Precision Medicine Through Multi-Omics: Clinical Insights from Xenotransplantation and Fibrosis". This session on October 16 promises to illuminate how multi-omic strategies are reshaping translational genomics. Leading experts such as Dr. Brendan Keating and Dr. Gloria Sheynkman are set to present groundbreaking findings that highlight the intersection of proteomics and genomics.
Highlights from Key Presentations
During the CoLab session, Dr. Keating will share findings on gene-edited pig organs transplanted into human patients. This presentation promises to showcase how integrated omics can illustrate significant immune responses and physiological dynamics. Meanwhile, Dr. Sheynkman's presentation on idiopathic pulmonary fibrosis highlights the potential of proteomic profiling in identifying biomarkers that can guide targeted therapies.
Innovations Presented by Seer Technology
In conjunction with the CoLab session, independent research teams will also present their findings utilizing Seer’s technology. These sessions reflect a growing trend in academic and clinical institutions globally, showcasing the Proteograph platform’s efficacy in providing deep proteomic insights. The data sourced from Seer’s platform significantly enhances prior findings, bridging gaps in disease research by seamlessly integrating proteomic information with genomic datasets.
Noteworthy Research Studies Featuring Seer
Among the highlighted studies, one focuses on the triangulation of various proteomic profiling methods to identify high-confidence protein targets, presented by Joshua Bis. Another significant study led by Claudia Langenberg delves into the prioritization of human knock-out mutations, offering fresh insights into gene functionality and clinical implications across multiple specialties.
Seer’s Commitment to Precision Medicine
Omid Farokhzad, Chair and CEO of Seer, expressed his enthusiasm about the rapid advancements in the field of proteomics. He noted, "Proteins are essential components driving biological functions, and understanding the proteome is crucial for advancing medical research. Our mission is to empower researchers with the tools they need to make pioneering discoveries that herald the next phase of precision medicine." Seer's commitment is evident in its robust workflow that consistently provides insights fostering innovative clinical applications.
About Seer, Inc.
Seer, Inc. (Nasdaq: SEER) is at the forefront of deep proteomics, offering high-throughput solutions that provide unparalleled insights into biological systems. The Proteograph Product Suite integrates proprietary technologies allowing for faster and more reliable proteomic data generation. Unlike traditional methods plagued by complexities and variable data quality, Seer’s systems are designed to deliver reproducible results, opening new avenues in biological research. It is critical to note that Seer's products are designated for research purposes only and not for clinical diagnostics.
Contact Information
For more insights into Seer’s innovative solutions, interested parties are welcome to visit booth #2586. Direct inquiries can be sent to the company at pr@seer.bio.
Media Contact:
Patrick Schmidt
pr@seer.bio
Investor Contact:
Carrie Mendivil
investor@seer.bio
Frequently Asked Questions
What is proteomics and why is it important?
Proteomics is the large-scale study of proteins, essential for understanding biological processes and disease mechanisms, leading to enhanced precision medicine.
How does Seer’s technology aid in research?
Seer's technology allows researchers to gather deep proteomic insights, effectively integrating genomic data to accelerate medical discoveries.
What sessions will Seer be hosting at the ASHG event?
Seer will feature a CoLab session focusing on multi-omic approaches to precision medicine, alongside several independent presentations using Seer’s platform.
Who are the key speakers featured in Seer’s session?
Dr. Brendan Keating and Dr. Gloria Sheynkman are notable speakers illustrating significant findings in their respective research areas.
What distinguishes Seer’s Proteograph from traditional proteomic methods?
The Proteograph offers high-throughput capabilities and consistent, reliable data, overcoming common challenges faced in traditional proteomics.
